A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumoursGabriel Mak, Hendrik‐Tobias Arkenau, Ivana Rizzuto et al.|British Journal of Cancer|2019Cited by 103
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098Nicholas F. Brown, Paul Mulholland, Graham Searle et al.|Neuro-Oncology|2018Cited by 83
ATNT-06EVALUATION OF THE SAFETY OF GSK2256098 AND PHARMACOKINETICS OF<sup>11</sup>C-GSK2256098 IN PATIENTS WITH RECURRENT GLIOBLASTOMA BY POSITRON EMISSION TOMOGRAPHY (PET) IMAGINGPaul Mulholland, Sarah P. Blagden, Jianping Zhang et al.|Neuro-Oncology|2015Cited by 3